These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Leippold T; Reitz A; Schurch B Eur Urol; 2003 Aug; 44(2):165-74. PubMed ID: 12875934 [TBL] [Abstract][Full Text] [Related]
7. Perspectives on urological care in multiple sclerosis patients. Moussa M; Abou Chakra M; Papatsoris AG; Dabboucy B; Hsieh M; Dellis A; Fares Y Intractable Rare Dis Res; 2021 May; 10(2):62-74. PubMed ID: 33996350 [TBL] [Abstract][Full Text] [Related]
8. Role of urodynamics in stress urinary incontinence: A critical appraisal. Yande SD; Joglekar OV; Joshi M J Midlife Health; 2016; 7(3):119-125. PubMed ID: 27721639 [TBL] [Abstract][Full Text] [Related]
9. Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis. Onal B; Siva A; Buldu I; Demirkesen O; Cetinel B Int Braz J Urol; 2009; 35(3):326-33. PubMed ID: 19538768 [TBL] [Abstract][Full Text] [Related]
10. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Kuo HC Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967 [TBL] [Abstract][Full Text] [Related]
11. Nonneurogenic voiding disorders in children and adolescents: clinical and videourodynamic findings in 4 specific conditions. Glassberg KI; Combs AJ; Horowitz M J Urol; 2010 Nov; 184(5):2123-7. PubMed ID: 20850821 [TBL] [Abstract][Full Text] [Related]
12. Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia. Huang M; Chen H; Jiang C; Xie K; Tang P; Ou R; Zeng J; Liu Q; Li Q; Huang J; Huang T; Zeng W J Rehabil Med; 2016 Oct; 48(8):683-687. PubMed ID: 27563834 [TBL] [Abstract][Full Text] [Related]
13. Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases. Wiedemann A; Kaeder M; Greulich W; Lax H; Priebel J; Kirschner-Hermanns R; Füsgen I World J Urol; 2013 Feb; 31(1):229-33. PubMed ID: 22227822 [TBL] [Abstract][Full Text] [Related]
14. Advances in the management of neurogenic detrusor overactivity in multiple sclerosis. Yonnet GJ; Fjeldstad AS; Carlson NG; Rose JW Int J MS Care; 2013; 15(2):66-72. PubMed ID: 24453765 [TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics and Urodynamic Analysis of Urinary Dysfunction in Multiple Sclerosis. Wang T; Huang W; Zhang Y Chin Med J (Engl); 2016 Mar; 129(6):645-50. PubMed ID: 26960366 [TBL] [Abstract][Full Text] [Related]
16. Management and rehabilitation of neurologic patients with lower urinary tract dysfunction. Drake MJ Handb Clin Neurol; 2015; 130():451-68. PubMed ID: 26003260 [TBL] [Abstract][Full Text] [Related]
17. Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction. Jiang YH; Chen SF; Kuo HC Int Neurourol J; 2020 Dec; 24(4):301-312. PubMed ID: 33401351 [TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150 [TBL] [Abstract][Full Text] [Related]
19. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Kuo HC Urology; 2005 Jul; 66(1):94-8. PubMed ID: 15992869 [TBL] [Abstract][Full Text] [Related]